Compare · BDX vs CAH
BDX vs CAH
Side-by-side comparison of Becton Dickinson and Company (BDX) and Cardinal Health Inc. (CAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BDX focuses on Medical/Dental Instruments, while CAH focuses on Other Pharmaceuticals.
- CAH is the larger of the two at $53.38B, about the same size as BDX ($52.30B).
- Over the past year, BDX is down 1.3% and CAH is up 57.1% - CAH leads by 58.4 points.
- CAH has been more active in the news (30 items in the past 4 weeks vs 9 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Cardinal Health Inc.
- Price
- $192.00+2.31%
- $229.54+0.44%
- Market cap
- $52.30B
- $53.38B
- 1M return
- +25.52%
- +1.68%
- 1Y return
- -1.34%
- +57.10%
- Industry
- Medical/Dental Instruments
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 9
- 30
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Latest BDX
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
- EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
Latest CAH
- Chief Accounting Officer Scherer Mary C. sold $546,473 worth of shares (2,302 units at $237.39), decreasing direct ownership by 45% to 2,811 units (SEC Form 4)
- Chief Executive Officer Hollar Jason M. sold $29,375,516 worth of shares (124,529 units at $235.89), decreasing direct ownership by 40% to 190,603 units (SEC Form 4)
- CEO, GMPD Segment Mason Stephen M sold $8,274,117 worth of shares (35,000 units at $236.40), decreasing direct ownership by 66% to 18,061 units (SEC Form 4)
- CEO, PSS Segment Weitzman Deborah sold $1,731,524 worth of shares (7,354 units at $235.45), decreasing direct ownership by 9% to 77,901 units (SEC Form 4)
- Chief Financial Officer Alt Aaron E sold $9,926,140 worth of shares (42,000 units at $236.34), decreasing direct ownership by 67% to 20,495 units (SEC Form 4)
- Chief Legal/Compliance Officer Mayer Jessica L sold $6,952,485 worth of shares (29,436 units at $236.19), decreasing direct ownership by 47% to 33,076 units (SEC Form 4)
- Chief Information Officer Greene Michelle D. sold $2,746,187 worth of shares (11,650 units at $235.72), decreasing direct ownership by 53% to 10,330 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cardinal Health with a new price target
- CEO, PSS Segment Weitzman Deborah was granted 7,314 shares and covered exercise/tax liability with 29,759 shares, decreasing direct ownership by 21% to 85,255 units (SEC Form 4) (for tax liability)
- CEO, GMPD Segment Mason Stephen M was granted 5,868 shares and covered exercise/tax liability with 25,289 shares, decreasing direct ownership by 27% to 53,061 units (SEC Form 4) (tax liability)